Recombinant human parathyroid hormone (1-34): pro-osteogenic action and application in oral field

doi:10.3969/j.issn.2095-4344.2731

Abstract

Abstract:

BACKGROUND: Recombinant human parathyroid hormone 1-34 (rhPTH 1-34), also known as teriparatide, is the amino terminal fragment of parathyroid hormone. Teriparatide, as a bone anabolic drug, has become a research hotspot because it can directly stimulate new bone formation and increase bone mass. It also attracts attention and application in the oral field due to its strong osteogenesis effect.

OBJECTIVE: To review the osteogenic mechanisms, efficacy and safety of teriparatide and its research progress in the oral field.

METHODS: The first author searched the PubMed and WanFang databases for relevant literature published over the past two decades. The keywords were “rhPTH(1-34); teriparatide; osteoporosis; stomatology; Jaw; implant-osseointegration; periodontal” in English and Chinese, respectively. Fifty-six eligible articles were finally reviewed.

RESULTS AND CONCLUSION: Teriparatide can directly stimulate the formation of osteoblasts in new bone and achieve effective anabolic metabolism. Studies of teriparatide in the oral field have shown good results in promoting implant-osseointegration, periodontal regeneration, bone defect healing and the stability of orthodontics, but increasing high-quality animal experiments and clinical studies are still needed. Future use of parathyroid hormone drugs and their analogues can be combined with bone tissue engineering technology to provide favorable effects in bone repair as well as in oral and maxillofacial repair.

Key words: Recombinant human parathyroid hormone (1-34), teriparatide, osteoporosis, stomatology, jaw, implant-osseointegration, periodontal

CLC Number:

Dong Xiling, Zhang Xiaoming, Liu Tongbin.

Recombinant human parathyroid hormone (1-34): pro-osteogenic action and application in oral field [J]. Chinese Journal of Tissue Engineering Research, 2020, 24(26): 4231-4236.

Figures/Tables 2

References

[1] 冯钰,刘福祥.骨质疏松症对颌骨的影响及其治疗的研究进展[J].国际口腔医学杂志,2008,35(S1):11-13.

[2] KANIS JA, COOPER C, RIZZOLI R, et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int. 2019; 104(3):235-238.

[3] POLYZOS SA, MAKRAS P, EFSTATHIADOU Z, et al. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opin Investig Drugs. 2015; 24(2):145-157.

[4] BARON R, HESSE E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab. 2012;97(2):311-325.

[5] BOGADO CE, MASSARI FE, ZANCHETTA JR. Parathyroid hormone (1-84) and teriparatide in the treatment of postmenopausal osteoporosis. Womens Health (Lond). 2006; 2(3):447-457.

[6] KEUTMANN HT, SAUER MM, HENDY GN, et al. Complete amino acid sequence of human parathyroid hormone. Biochemistry. 1978;17(26):5723-5729.

[7] LANGDAHL BL, ANDERSEN JD. Treatment of Osteoporosis: Unmet Needs and Emerging Solutions. J Bone Metab. 2018;25(3): 133-140.

[8] 王敏娇,司家文,沈国芳.促进骨形成的甲状旁腺激素:作用及机制[J].中国组织工程研究,2015,19(15):2405-2409.

[9] 陈茜,曹国颖.新型骨质疏松症治疗药abaloparatide的作用机制与临床评价[J].临床药物治疗杂志,2018,16(7):37-40.

[10] BELLIDO T, ALI AA, PLOTKIN LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003;278(50):50259-50272.

[11] QIN L, LI X, KO JK, et al. Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem. 2005;280(4):3104-3111.

[12] JILKA RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40(6):1434-1446.

[13] WINKLER DG, SUTHERLAND MK, GEOGHEGAN JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22(23):6267-6276.

[14] KHOSLA S, WESTENDORF JJ, OURSLER MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008; 118(2):421-428.

[15] BIKLE DD, SAKATA T, LEARY C, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002;17(9):1570-1578.

[16] FOX J. Developments in parathyroid hormone and related peptides as bone-formation agents. Curr Opin Pharmacol. 2002;2(3):338-344.

[17] NEER RM, ARNAUD CD, ZANCHETTA JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.

[18] YOO JI, HA YC, RYU HJ, et al. Teriparatide Treatment in Elderly Patients With Sacral Insufficiency Fracture. J Clin Endocrinol Metab. 2017;102(2):560-565.

[19] KITAGUCHI K, KASHII M, EBINA K, et al. Effects of Weekly Teriparatide Administration for Vertebral Stability and Bony Union in Patients with Acute Osteoporotic Vertebral Fractures. Asian Spine J. 2019;13(5):763-771.

[20] CHEN Q, GUO M, MA X, et al. Adherence to Teriparatide Treatment and Risk of Fracture: A Systematic Review and Meta-Analysis. Horm Metab Res. 2019;51(12):785-791.

[21] 徐陆晨,李运峰.骨质疏松性骨折药物治疗的研究进展[J].中国骨质疏松杂志,2017,23(7):947-953.

[22] ANDREWS EB, GILSENAN A, MIDKIFF K, et al. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma. Ann Epidemiol. 2016;26(11):751-753.

[23] DRAKE MT, SRINIVASAN B, MÖDDER UI, et al. Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone. 2011;49(3):349-355.

[24] GREY A. Teriparatide for bone loss in the jaw. N Engl J Med. 2010;363(25):2458-2459.

[25] PAZIANAS M. Anabolic effects of PTH and the 'anabolic window'. Trends Endocrinol Metab. 2015;26(3):111-113.

[26] NAKAMURA T, SUGIMOTO T, NAKANO T, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97(9):3097-3106.

[27] USUI T, FUNAGOSHI M, SETO K, et al. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis. Arch Osteoporos. 2018;13(1):54.

[28] KUMAGAI Y, OSE A, TANAKA K, et al. Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study. Clin Pharmacol Drug Dev. 2020;9(1):87-96.

[29] COSMAN F, LANE NE, BOLOGNESE MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95(1): 151-158.

[30] HÄMMERLE SP, MINDEHOLM L, LAUNONEN A, et al. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone. 2012;50(4):965-973.

[31] PEARSON RG, MASUD T, BLACKSHAW E, et al. Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. Pharmaceutics. 2019;11(6): E265.

[32] GUAÑABENS N, MORO-ÁLVAREZ MJ, CASADO E, et al. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. Endocrine. 2019;64(3): 441-455.

[33] VOHRA F, AL-RIFAIY MQ, ALMAS K, et al. Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies. Arch Oral Biol. 2014;59(9):912-920.

[34] BEPPU K, KIDO H, WATAZU A, et al. Peri-implant bone density in senile osteoporosis-changes from implant placement to osseointegration. Clin Implant Dent Relat Res. 2013;15(2): 217-226.

[35] DARCEY J, HORNER K, WALSH T, et al. Tooth loss and osteoporosis: to assess the association between osteoporosis status and tooth number. Br Dent J. 2013;214(4):E10.

[36] ANIL S, PREETHANATH RS, ALMOHARIB HS, et al. Impact of osteoporosis and its treatment on oral health. Am J Med Sci. 2013;346(5):396-401.

[37] SHIROTA T, TASHIRO M, OHNO K, et al. Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats. J Oral Maxillofac Surg. 2003;61(4):471-480.

[38] ALMAGRO MI, ROMAN-BLAS JA, BELLIDO M, et al. PTH [1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis. Clin Oral Implants Res. 2013;24(9): 1027-1034.

[39] JIANG L, ZHANG W, WEI L, et al. Early effects of parathyroid hormone on vascularized bone regeneration and implant osseointegration in aged rats. Biomaterials. 2018;179:15-28.

[40] KUCHLER U, LUVIZUTO ER, TANGL S, et al. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. J Dent Res. 2011;90(8):1001-1006.

[41] KRAUS D, JÄGER A, ABUDUWALI N, et al. Intermittent PTH(1-34) signals through protein kinase A to regulate osteoprotegerin production in human periodontal ligament cells in vitro. Clin Oral Investig. 2012;16(2):611-618.

[42] AUSENDA F, RASPERINI G, ACUNZO R, et al. New Perspectives in the Use of Biomaterials for Periodontal Regeneration. Materials (Basel). 2019;12(13): E2197.

[43] VASCONCELOS DF, MARQUES MR, BENATTI BB, et al. Intermittent parathyroid hormone administration improves periodontal healing in rats. J Periodontol. 2014;85(5):721-728.

[44] SILVA MA, VASCONCELOS DF, MARQUES MR, et al. Parathyroid hormone intermittent administration promotes delay on rat incisor eruption. Arch Oral Biol. 2016;69:102-108.

[45] DE OLIVEIRA PUTTINI I, GOMES-FERREIRA PHDS, DE OLIVEIRA D, et al. Teriparatide improves alveolar bone modelling after tooth extraction in orchiectomized rats. Arch Oral Biol. 2019; 102:147-154.

[46] BASHUTSKI JD, EBER RM, KINNEY JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 2010; 363(25):2396-2405.

[47] LI F, LI G, HU H, et al. Effect of parathyroid hormone on experimental tooth movement in rats. Am J Orthod Dentofacial Orthop. 2013;144(4):523-532.

[48] LOSSDÖRFER S, YILDIZ F, GÖTZ W, et al. Anabolic effect of intermittent PTH(1-34) on the local microenvironment during the late phase of periodontal repair in a rat model of tooth root resorption. Clin Oral Investig. 2010;14(1):89-98.

[49] ZANDI M, DEHGHAN A, GHEYSARI F, et al. Evaluation of teriparatide effect on healing of autografted mandibular defects in rats. J Craniomaxillofac Surg. 2019;47(1):120-126.

[50] ZANDI M, DEHGHAN A, AMINI P, et al. Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw. Clin Oral Investig. 2019;23(11):3987-3993.

[51] KAKEHASHI H, ANDO T, MINAMIZATO T, et al. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg. 2015;44(12):1558-1564.

[52] KIM JY, PARK JH, JUNG HD, et al. Treatment of Medication-Related Osteonecrosis of the Jaw Around the Dental Implant With a Once-Weekly Teriparatide: A Case Report and Literature Review. J Oral Implantol. 2019;45(5):403-407.

[53] JUNG J, YOO HY, KIM GT, et al. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study. J Bone Miner Res. 2017;32(12): 2445-2452.

[54] CHA YH, HONG N, RHEE Y, et al. Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw. Osteoporos Int. 2018; 29(4):987-992.

[55] VALDERRAMA P, JUNG RE, THOMA DS, et al. Evaluation of parathyroid hormone bound to a synthetic matrix for guided bone regeneration around dental implants: a histomorphometric study in dogs. J Periodontol. 2010;81(5):737-747.

[56]ÖZER T, BAŞLARLI Ö, AKTAŞ A, et al. Locally administrated single-dose teriparatide affects critical-size rabbit calvarial defects: A histological, histomorphometric and micro-CT study. Acta Orthop Traumatol Turc. 2019;53(6):478-484.